@article{f88b11e5b6d64aa2bff91caed5aa7e17,
title = "An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening",
abstract = "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro.",
keywords = "COVID-19, COVID19, SARS-CoV-2, antivirals, medium-throughput screening, microneutralization, neutralization",
author = "Fatima Amanat and White, {Kris M.} and Lisa Miorin and Shirin Strohmeier and Meagan McMahon and Philip Meade and Liu, {Wen Chun} and Albrecht, {Randy A.} and Viviana Simon and Luis Martinez-Sobrido and Thomas Moran and Adolfo Garc{\'i}a-Sastre and Florian Krammer",
note = "Funding Information: This work was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C (F.K., A.G.‐S.), Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 (F.K., A.G.‐S.), DARPA project HR0011‐19‐2‐0020 (A.G.‐S.), and the generous support of the JPB foundation, the Open Philanthropy Project (#2020‐215611 to A.G.‐S.), and other philanthropic donations. Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",
year = "2020",
month = sep,
day = "1",
doi = "10.1002/cpmc.108",
language = "English",
volume = "58",
journal = "Current Protocols in Microbiology",
issn = "1934-8525",
publisher = "John Wiley & Sons Inc.",
number = "1",
}